| Neda Shahriari, | |
|
221 Longwood Ave, Boston, MA 02115-5817 | |
| (203) 915-8091 | |
| Not Available |
| Full Name | Neda Shahriari |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 221 Longwood Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265963979 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 292115 (Massachusetts) | Primary |
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
Although women have little or no control over some of the risk factors for breast cancer, such as those related to aging and genetics, they may be able to reduce their chances for developing the disease by avoiding certain environmental risks. BREAST CANCER AND THE ENVIRONMENT: A LIFE COURSE APPROACH, a new report from the Institute of Medicine, assesses the breast cancer risk posed by various environmental factors, identifies actions that offer potential to reduce women's risk for the disease, and recommends targets for future research.
"Signaling the latest step forward in rapidly strengthening U.S.-Somalia relations, the administrator of the U.S. Agency for International Development spent five hours in Mogadishu on Thursday, the highest ranking U.S. administration official to visit Somalia's capital in years," the Associated Press reports.
A new report by the National Academies of Sciences, Engineering, and Medicine proposes a strategy that the U.S. Environmental Protection Agency should use to evaluate the evidence of adverse human health effects from low doses of exposure to chemicals that can disrupt the endocrine system.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
› Verified 2 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Although women have little or no control over some of the risk factors for breast cancer, such as those related to aging and genetics, they may be able to reduce their chances for developing the disease by avoiding certain environmental risks. BREAST CANCER AND THE ENVIRONMENT: A LIFE COURSE APPROACH, a new report from the Institute of Medicine, assesses the breast cancer risk posed by various environmental factors, identifies actions that offer potential to reduce women's risk for the disease, and recommends targets for future research.
"Signaling the latest step forward in rapidly strengthening U.S.-Somalia relations, the administrator of the U.S. Agency for International Development spent five hours in Mogadishu on Thursday, the highest ranking U.S. administration official to visit Somalia's capital in years," the Associated Press reports.
A new report by the National Academies of Sciences, Engineering, and Medicine proposes a strategy that the U.S. Environmental Protection Agency should use to evaluate the evidence of adverse human health effects from low doses of exposure to chemicals that can disrupt the endocrine system.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neda Shahriari, 12 Pinnacle Rd, Farmington, CT 06032-3006 Ph: (203) 915-8091 | Neda Shahriari, 221 Longwood Ave, Boston, MA 02115-5817 Ph: (203) 915-8091 |
News Archive
Although women have little or no control over some of the risk factors for breast cancer, such as those related to aging and genetics, they may be able to reduce their chances for developing the disease by avoiding certain environmental risks. BREAST CANCER AND THE ENVIRONMENT: A LIFE COURSE APPROACH, a new report from the Institute of Medicine, assesses the breast cancer risk posed by various environmental factors, identifies actions that offer potential to reduce women's risk for the disease, and recommends targets for future research.
"Signaling the latest step forward in rapidly strengthening U.S.-Somalia relations, the administrator of the U.S. Agency for International Development spent five hours in Mogadishu on Thursday, the highest ranking U.S. administration official to visit Somalia's capital in years," the Associated Press reports.
A new report by the National Academies of Sciences, Engineering, and Medicine proposes a strategy that the U.S. Environmental Protection Agency should use to evaluate the evidence of adverse human health effects from low doses of exposure to chemicals that can disrupt the endocrine system.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
› Verified 2 days ago
Erica Dommasch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Shapiro 2, Boston, MA 02215 Phone: 617-667-3753 | |
Dr. Chantal Louise Cotter, MB BCH BAO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
Dr. John J Croke, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Debjani Sahni, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Joseph C Kvedar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Staniford St, Suite 200, Boston, MA 02114 Phone: 617-726-2914 Fax: 617-724-2135 | |
Ryan Char Kelm, Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St # 250, Boston, MA 02114 Phone: 617-724-6960 | |
Dr. David Attar Hashemi, MD, MBA Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St, Boston, MA 02114 Phone: 617-726-2914 |